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Abstract
Genetically engineered mouse models of cancer can be used to
filter genome-wide expression datasets generated from human
tumours and to identify gene expression alterations that are
functionally important to cancer development and progression.
In this study, we have generated RNAseq data from tumours
arising in two established mouse models of prostate cancer,
PB-Cre/PtenloxP/loxP and p53loxP/loxPRbloxP/loxP, and integrated this
with published human prostate cancer expression data to
pinpoint cancer-associated gene expression changes that are
conserved between the two species. To identify potential
therapeutic targets, we then filtered this information for genes
that are either known or predicted to be druggable. Using
this approach, we revealed a functional role for the kinase
MELK as a driver and potential therapeutic target in prostate
cancer. We found that MELK expression was required for cell
survival, affected the expression of genes associated with pros-
tate cancer progression and was associated with biochemical
recurrence.
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Introduction
Prostate cancer is the second most frequent cancer in men globally
(Torre et al, 2015). As the androgen receptor (AR) is the main onco-
genic driver in prostate cancer, most drugs used for the treatment of
this disease are aimed at inhibiting AR activity (Aragon-Ching,
2014). However, resistance to both first- and second-line androgen
deprivation therapies (ADT) commonly occurs (Yuan et al, 2014),
illustrating the importance of identifying additional therapeutic
targets for prostate cancer treatment.
The generation of genome-wide expression datasets from human
prostate tumours readily allows the identification of genes whose
expression levels are altered during cancer development and
progression (Glinsky et al, 2004; Taylor et al, 2010; Grasso et al,
2012; Cancer Genome Atlas Research Network et al, 2015; Ross-
Adams et al, 2015). However, translating this information into clini-
cally useful therapeutic targets poses a twofold challenge: firstly,
many genes may be aberrantly expressed as a consequence of
cancer development without directly contributing to it, and
secondly, not all functionally important genes will represent action-
able targets for current drug development approaches.
A number of genetically engineered mouse models (GEMM) of
prostate cancer have been developed, and triangulating the findings
from genome-wide expression datasets from human cancers with
those from well-characterised mouse models may provide a useful
filter to prioritise genes that are functionally important to cancer
development (Robles-Espinoza & Adams, 2014). Previous studies in
various cancer types have demonstrated that integration of gene
expression or copy number alteration data from human and murine
tumours is a viable approach to derive diagnostic, prognostic or
predictive signatures (Belmont et al, 2014) and to identify candidate
driver genes (Ellwood-Yen et al, 2003; Tompkins et al, 2013).
In prostate cancer, cross-species approaches are particularly
1 Uro-oncology Research Group, CRUK Cambridge Institute, Cambridge, UK
2 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
3 Department of Urology, University of Cambridge, Cambridge, UK
4 Department of Oncology, Addenbrooke’s Hospital, Cambridge, UK
5 Bioinformatics Core Facility, CRUK Cambridge Institute, Cambridge, UK
6 Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
7 MRC-Laboratory of Molecular Biology, Cambridge, UK
8 Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
9 Department of Morphology, Institute of Biosciences of Botucatu, Sao Paulo State University (UNESP), Sao Paulo, Brazil
*Corresponding author. Tel: +44 1223 943698; E-mail: sarah@jurmeister.eu
†These authors contributed equally to this work
ª 2018 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 10: e8274 | 2018 1 of 18
Published online: February 5, 2018 
challenging because the mouse prostate is anatomically very dif-
ferent from the human prostate. In contrast to the adult human
prostate, the mouse prostate can be divided into histologically
distinct lobes: the anterior prostate (AP), ventral prostate (VP),
lateral prostate (LP) and dorsal prostate (DP) (Shappell et al, 2004).
It has been suggested that the dorsolateral mouse prostate resembles
the human peripheral zone (Berquin et al, 2005) where most pros-
tate cancers arise, but this remains a point of debate (Shappell et al,
2004; Irshad & Abate-Shen, 2013). Moreover, to date, no single
GEMM by itself is able to faithfully model all aspects of the natural
history of prostate cancer (Irshad & Abate-Shen, 2013).
Despite these challenges, two recent publications using such
cross-species approaches have reported a synergistic interaction
between FOXM1 and CENPE (Aytes et al, 2014) and established a
potential role for MET amplifications in prostate cancer (Wanjala
et al, 2014), demonstrating the utility of using GEMM as biological
filters in the study of this cancer type. However, the full potential of
cross-species comparisons to systematically identify and validate
druggable targets has not yet been realised. The number of poten-
tially druggable genes in the human genome has been estimated at
~3,000 (Hopkins & Groom, 2002). This represents only 5% of all
annotated genes (15% of protein-coding genes), and thus, the
majority of genes that are linked to cancer development or progres-
sion do not likely make suitable targets for drugs. Taking these
considerations into account when prioritising hits from cross-species
studies for follow-up validation should thus result in a more
focussed identification of potential therapeutic targets.
In this study, we have used next-generation sequencing to obtain
detailed gene expression information from different stages of
tumour development and progression in two established GEMM
of prostate cancer: the PB-Cre/PtenloxP/loxP model, which develops
castration-sensitive, invasive but rarely metastasising cancer (Wang
et al, 2003; Svensson et al, 2011), and the PB-Cre/p53loxP/loxPRbloxP/
loxP model, which develops metastatic castration-resistant prostate
cancer (Zhou et al, 2006). Together, these two models represent
useful tools to study both indolent and advanced prostate cancer.
Furthermore, deletions and mutations of the tumour suppressors
Pten, p53 and Rb are among the most common genomic alterations
in human prostate cancer, with two-thirds of prostate cancers show-
ing alterations in at least one of the three genes (Appendix Fig S1A).
We have integrated the genomic data obtained from these models
with published human prostate cancer expression data and filtered
them for potentially druggable genes. Using this approach, we have
identified maternal embryonic leucine zipper kinase (MELK) as a
potential therapeutic target in prostate cancer. We have then validated
the functional importance of MELK for tumour growth both in vitro
and in vivo and identified a new mechanism through which this
kinase may drive proliferation and viability of prostate cancer cells.
Results
Generation of genome-wide expression data representing
different stages of murine prostate cancer development
and progression
We analysed the histopathology and transcriptomic landscape
of prostate tumours arising in all four lobes of the PB-Cre/
p53loxP/loxPRbloxP/loxP and PB-Cre/PtenloxP/loxP mouse models of
prostate cancer at three different stages of tumour development and
progression in order to derive specific signatures for them. A total of
94 samples were selected for further RNAseq analysis, including 20
normal prostatic lobes as well as PIN and tumours from both mouse
models (Table EV1). In contrast to a recent publication reporting
that high-quality RNA can only be obtained from the lateral and
ventral lobes (Zingiryan et al, 2017), we were able to obtain RNA
with sufficient RNA quality from all lobes (Table EV1).
In the PB-Cre/PtenloxP/loxP model, all four lobes developed PIN
that progressed to invasive adenocarcinoma, albeit with varying
kinetics; for example, tumours developing in the AP displayed a
delayed progression as compared to the other three lobes, consistent
with previous reports (Fig 1A; Wang et al, 2003; Svensson et al,
2011). It is currently unknown whether tumours arising in one lobe
resemble human prostate cancer more closely than those arising in
others; therefore, we analysed all four lobes separately. Further-
more, to represent different stages of tumour progression, lesions
observed in this model were divided into PIN (regions of low-grade
and high-grade PIN, predominant in the glands from animals at ages
of 3–7 months), medium-stage tumours (regions with high-grade
PIN, microinvasive adenocarcinoma and stromal desmoplastic reac-
tion, predominant in prostatic lobes of animals older than
8 months) and advanced-stage tumours (regions with well-differen-
tiated, moderately differentiated and poorly differentiated, frankly
invasive adenocarcinoma, predominant in the prostatic lobes of
animals older than 12 months) (Fig 1A–D, Appendix Fig S1B). In
contrast, PB-Cre/p53loxP/loxPRbloxP/loxP mice developed low-grade
PIN in the four lobes (animals older than 4 months), but the aggres-
sive, metastatic tumours that develop in these mice arise from the
proximal region of the ducts near the urethra (found in virtually all
animals older than 5 months), consistent with previous observa-
tions (Zhou et al, 2007). Therefore, periurethral tumours were
included in the study in addition to PIN lesions from all four lobes
(Fig 1E and F).
Expression profiling reveals the dynamics of gene expression
changes during prostate cancer progression
By selecting samples representing different anatomical regions and
stages of tumour progression, our study design provided us with the
opportunity to uncover the genetic programmes contributing to
prostate cancer development. The pattern of genes expressed in
normal mouse prostate lobes was sufficiently distinct for the wild-
type samples to be clearly separated by hierarchical clustering
according to their lobe of origin (Fig 2A and B). In contrast, in PIN
lesions and tumours in the PB-Cre/PtenloxP/loxP model, this distinc-
tion was lost (Fig 2A). PIN lesions, medium-stage tumours and
advanced-stage tumours were separated from normal samples, but
not from each other, although there was a trend for the advanced-
stage tumours to cluster together. Conversely, in the PB-Cre/p53loxP/
loxPRbloxP/loxP model, PIN and normal samples largely clustered
together while tumours were highly distinct (Fig 2B). Taken
together, these observations are consistent with the distinct natural
histories of tumorigenesis in the two models, with PIN lesions and
invasive carcinoma representing a continuum of tumour progression
in the PB-Cre/PtenloxP/loxP model, while the PIN lesions and tumours
in the PB-Cre/p53loxP/loxPRbloxP/loxP model are distinct entities.
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Due to the slow progression and involvement of all four lobes of
the PB-Cre/PtenloxP/loxP model in all stages of tumour progression,
we used the data derived from this model to further investigate
whether subsets of gene expression alterations could be linked to
specific prostate lobes or stages of tumour progression. PIN lesions
and tumours arising in the PB-Cre/PtenloxP/loxP model could not be
clearly differentiated based on their lobe of origin. This finding
suggested that at least some of the gene expression changes that
occurred during tumorigenesis were similar between lobes. Indeed,
a comparison of genes that were differentially expressed in tumours
of the four lobes relative to normal prostate revealed that, while
some gene expression changes were unique to a particular lobe, the
majority were shared with at least one other lobe (Fig 2C). By
selecting the genes that were differentially expressed in all four
lobes in a given stage of tumorigenesis, we were thus able to create
expression signatures that were associated with PIN lesions,
medium-stage tumours (MedTumour) and advanced-stage tumours
(AdTumour) in the PB-Cre/PtenloxP/loxP model.
When comparing these three expression signatures of the PB-
Cre/PtenloxP/loxP model, we found that there was a core set of 351
genes (262 upregulated and 89 downregulated) that was already
aberrantly expressed in PIN lesions and remained dysregulated
throughout the subsequent stages of tumour progression (Fig 2D).
Progression to medium-stage and advanced-stage tumours resulted
in the acquisition of additional gene expression alterations. While
some differentially expressed genes (DEGs) were specific to PIN
lesions or medium-stage tumours, advanced-stage tumours had the
highest number of unique gene expression alterations.
To gain insight into the biological processes associated with
tumour progression in the PB-Cre/PtenloxP/loxP model, we performed
MetaCoreTM enrichment analyses on three different gene sets: genes
that were aberrantly expressed in all three stages of tumour progres-
sion (“All Stages”, n = 351); genes that were aberrantly expressed
in both medium-stage and advanced-stage tumours, but not in PIN
lesions (“Tumour-Specific”, n = 220); and genes that were only
aberrantly expressed in advanced-stage tumours (“AdTumour-
Specific”, n = 339). For each gene set, we ranked all significantly
enriched process networks according to the P-value of the enrich-
ment and compared these ranks between the three gene sets
(Fig 2E). We found that the core set of genes that were altered in all
three stages of progression was highly enriched for genes related to
cell cycle control. Additional changes in cell cycle-related genes
occurred during progression to adenocarcinoma, as shown by the
enrichment for these processes in the “Tumour-Specific” gene set,
whereas we observed no significant enrichment for these biological
processes among genes that were only dysregulated in advanced-
stage tumours. Similarly, a significant number of changes in the
expression of cytoskeletal genes occurred during progression both
from normal prostate to PIN and from PIN to carcinoma, but not
from medium-stage tumours to advanced-stage tumours. Process
networks related to inflammation and immune response were
enriched among all three gene sets, but the signalling pathways
associated with the different stages of progression were largely
distinct. Finally, blood vessel morphogenesis was the most enriched
process network among “AdTumour-Specificfic” genes, and the
enrichment for this biological process was unique to this gene set.
Taken together, these analyses reveal the dynamics of gene expres-
sion and cellular pathways that are important during the different
stages of tumour progression.
Human and murine prostate tumours share a common set of
gene expression alterations
An important point to consider when interpreting findings obtained
from GEMM of cancer is how well the chosen model resembles the
human disease. Thus, we next aimed to understand whether the
gene expression signatures we derived from tumours arising in
mouse models were relevant for the investigation of human prostate
cancer. In human prostate cancer, an established and clinically vali-
dated cell cycle progression (CCP) score consisting of 31 genes can
be used to distinguish indolent from aggressive prostate cancer
(Cuzick et al, 2011). Examining the mouse homologues of the CCP
signature genes, we found that in the PB-Cre/PtenloxP/loxP model,
these genes were progressively upregulated during tumour progres-
sion and were uniformly highly expressed in the very aggressive PB-
Cre/p53loxP/loxPRbloxP/loxP model (Fig 3A). We also assessed a gene
expression signature driven by the transcription factor HES6 which
has been implicated in prostate cancer progression and resistance to
castration (Ramos-Montoya et al, 2014). The mouse homologues of
these HES6 signature genes were also strongly upregulated in the
aggressive, castration-resistant PB-Cre/p53loxP/loxPRbloxP/loxP model,
but largely unchanged in the slowly progressing, castration-sensitive
PB-Cre/PtenloxP/loxP model (Fig EV1A). This suggested that similar
genes may be contributing to aggressiveness in both human and
murine prostate tumours.
To further address this question, we used gene set enrichment
analysis (GSEA) to compare genes that were aberrantly expressed in
murine prostate tumours to a published human prostate cancer
dataset (Grasso et al, 2012). We found that genes that were deregu-
lated in tumours of both the PB-Cre/PtenloxP/loxP and the PB-Cre/
p53loxP/loxPRbloxP/loxP model showed predominantly similar expres-
sion patterns in human tumours (Fig 3B). Notably, the strongest
enrichments were only obtained by taking into account information
from all four murine prostate lobes and both models (Fig EV1B). In
◀ Figure 1. Representative histopathological images of the GEMM prostatic lobes.A Wild-type prostate from Cre-negative PtenloxP/loxP mice.
B–D Stages of cancer development and progression in PB-Cre/PtenloxP/lox mice. PIN: prostatic intraepithelial neoplasia; MedTumour: medium-stage tumour; AdTumour:
advanced-stage tumour.
E Low-grade PIN in PB-Cre/p53loxP/loxPRbloxP/loxP mice (arrows).
F Prostate tumour arising from the stem/progenitor cell-enriched proximal region of prostatic ducts, shown in two magnifications. AP: anterior prostate; VP: ventral
prostate; LP: lateral prostate; DP: dorsal prostate; SV: seminal vesicle; UM: urethral muscle.
Data information: Scale bars correspond to 200 lm, except (F), left: 2 mm.
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particular, we found that data from individual lobes in the PB-Cre/
PtenloxP/loxP model poorly identified genes upregulated in human
prostate cancer.
Taken together, our data suggest that human and murine pros-
tate cancers share a common set of gene expression changes and
that similar genes contribute to cancer progression in both species.
Cross-species analysis identifies potential therapeutic targets in
prostate cancer
Having established that murine and human prostate tumours exhibit
common gene expression alterations, we hypothesised that integrat-
ing information from both species would enable us to enrich for
functionally important genes and thus potential novel therapeutic
targets. We thus selected all genes that were significantly dysregu-
lated in tumours of both mouse models (“Pten model (all lobes) and
p53/Rb model” in Fig EV1B) and in human prostate cancers and fil-
tered them using The Drug Gene Interaction Database (DGIdb;
http://dgidb.genome.wustl.edu/) to enrich for genes that are
predicted to be druggable (Griffith et al, 2013; Fig 3C). Furthermore,
as most targeted cancer therapies in use today are inhibitors of
molecular targets, rather than activators (Abramson, 2014), we
chose to focus on genes whose expression was increased in prostate
tumours. By using these multiple levels of filtering, we were able to
identify 10 potential therapeutic targets (Fig 3D), of which nine
were also highly expressed in a second independent prostate cancer
dataset (Fig EV2A; Ross-Adams et al, 2015). Notably, this group
included several key cell cycle regulators (e.g. Bub1, Bub1b,
Cdc25c, Cdk1).
To further narrow down this list to the most promising therapeu-
tic targets, we investigated whether the high expression of any of
the candidate genes was associated with poor outcome (decreased
relapse-free survival) in four published prostate cancer datasets
(Glinsky et al, 2004; Taylor et al, 2010; Ross-Adams et al, 2015).
Six out of ten genes displayed a statistically significant association
with outcome in at least one of the four datasets, suggesting that
our approach did indeed uncover a number of genes that are likely
to be of functional relevance. In every single one of these cases,
high expression of the gene was linked to decreased relapse-free
survival (Fig EV2B). One of these genes (MELK) correlated with
poor outcome in all datasets (Figs 4A and EV2B and C).
Furthermore, in the Cambridge and Stockholm datasets, MELK is
among a list of 100 strongest genes that stratify prostate cancers into
distinct molecular subgroups with different clinical outcomes based
on integration of copy number and transcript data from radical
prostatectomy specimens (Ross-Adams et al, 2015). Indeed, the
expression of MELK tends to be higher in groups associated with
poor prognosis (iCluster 1, iCluster 3 and iCluster 5) than those
associated with good prognosis (iCluster 2 and iCluster 4; Figs 4B
and EV2D; Ross-Adams et al, 2015; Dunning et al, 2017). A number
of publications suggest that MELK may play an important function
in various cancer types, particularly in brain and breast cancers
(Marie et al, 2008; Hebbard et al, 2010; Gu et al, 2013; Wang et al,
2014). Nevertheless, the molecular mechanisms underlying MELK
function in promoting cancer progression remain poorly under-
stood, at least in prostate cancer, and so far, although we have
found MELK to be consistently upregulated across multiple prostate
cancer datasets (Fig EV2E), only two publications have reported a
potential role in prostate cancer (Kuner et al, 2013; Ross-Adams
et al, 2015). Therefore, due to its emerging role as a potential thera-
peutic target in multiple cancers, as well as the recent development
of a small-molecule MELK inhibitor (Chung et al, 2012), we selected
this kinase for further study in order to determine its value as a
potential therapeutic target in prostate cancer.
MELK is overexpressed in human prostate tumours and
associated with aggressiveness
After first validating the overexpression of MELK mRNA in a
second, independent set of PB-Cre/PtenloxP/loxP and the PB-Cre/
p53loxP/loxPRbloxP/loxP prostate tumour samples (Fig EV3A), we
aimed to confirm that MELK expression is also increased at the
protein level in these tumours. We were able to demonstrate
increased levels of MELK protein in PIN lesions, medium-stage and
advanced-stage tumours in the PB-Cre/PtenloxP/loxP model, and in
PIN, primary tumours and liver metastases in the PB-Cre/p53loxP/
loxPRbloxP/loxP model by immunohistochemistry (IHC) (Fig EV3B–D).
We then tested whether MELK protein was also overexpressed in
human cancers using a tissue microarray. We found that, while the
majority (~70%) of non-neoplastic samples were negative for MELK
expression, ~60% of PIN samples and more than 80% of tumour
samples stained positively (Fig 4C and D). About half of the rare
◀ Figure 2. Transcriptomic landscape of prostate tumours arising in the PB-Cre/PtenloxP/loxP and PB-Cre/p53loxP/loxPRbloxP/loxP models.A Sample distance heatmap showing the clustering of normal tissue, PIN, medium-stage tumours (MedTumour) and advanced-stage tumours (AdTumour) derived from
the four murine prostatic lobes in PB-Cre/PtenloxP/loxP mice based on their gene expression profile as assessed by RNA sequencing.
B Sample distance heatmap showing the clustering of normal tissue and PIN derived from the four murine prostatic lobes and aggressive, proximal zone-derived
tumours in PB-Cre/p53loxP/loxPRbloxP/loxP mice based on their gene expression profile as assessed by RNA sequencing.
C Venn diagrams showing the derivation of PIN-, MedTumour- and AdTumour-associated gene expression signatures in the PB-Cre/PtenloxP/loxP model. Differentially
expressed genes (DEG) in PIN, medium-stage tumours and advanced-stage tumours of all lobes were identified relative to their respective wild-type lobe of origin
(Padj < 0.05). Genes that were significantly upregulated or downregulated in PIN, medium-stage tumours or advanced-stage tumours in all four lobes are depicted in
heatmaps.
D Overlaps between the PIN, MedTumour and AdTumour gene expression signatures. PIN: prostatic intraepithelial neoplasia; MedTumour: medium-stage tumour;
AdTumour: advanced-stage tumour.
E MetaCoreTM enrichment analyses for process networks on three gene sets: aberrantly expressed in all three stages of tumour progression (“All Stages”, n = 351);
aberrantly expressed in both medium-stage and advanced-stage tumours, but not in PIN lesions (“Tumour-Specific”, n = 220); aberrantly expressed in advanced-stage
tumours only (“AdTumour-specific”, n = 384). For each gene set, significantly enriched process networks (P < 0.01) were ranked according to their P-value. The lists of
enriched process network terms were combined, and their ranks across all three gene sets are shown as a heatmap. n.s.: not significantly enriched in this gene set.
Source data are available online for this figure.
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MELK-positive non-neoplastic cases displayed exclusively nuclear
staining; in contrast, MELK staining in PIN and tumour samples was
either exclusively cytoplasmic or both cytoplasmic and nuclear, but
rarely exclusively nuclear. Interestingly, a similar pattern was
observed when comparing tumours with different degrees of aggres-
siveness. Cytoplasmic, but not nuclear, expression of MELK was
associated with increased Gleason score and higher tumour stage
(Fig 4E). Taken together, these results confirmed that MELK protein
was indeed overexpressed in prostate cancer, and suggested that
cytoplasmic MELK was associated with tumour progression.
Abrogation of MELK activity represses genes associated with
tumour progression and reduces proliferation and viability of
prostate cancer cells
We then set out to investigate the effects of MELK abrogation on
prostate cancer cells in vitro. As MELK is most highly expressed in
aggressive prostate tumours, we chose the metastatic, castration-
resistant C4-2b cell line as our main model system. A potent small-
molecule inhibitor of MELK, OTS167, has been developed (Chung
et al, 2012) and in our hands inhibited phosphorylation of the
known MELK substrate ACC (Beullens et al, 2005) at nanomolar
concentrations (Fig EV4A), indicating successful inhibition of MELK
under these experimental conditions. Treatment with OTS167 also
reduced MELK protein levels, which has been previously observed
and is attributed to decreased MELK stability due to inhibition of
autophosphorylation (Lizcano et al, 2004; Badouel et al, 2010;
Chung et al, 2016). We performed RNA sequencing following either
knock-down of MELK with two different siRNAs (Fig EV4B) or treat-
ment with OTS167. It is well known that both siRNAs and small-
molecule inhibitors can have off-target effects, and indeed, a recent
publication indicated that OTS167 can inhibit other kinases
(although to a lesser extent than MELK) (Ji et al, 2016). Neverthe-
less, there was considerable overlap between genes that were
dysregulated following MELK knock-down and following OTS167
treatment (Fig EV4C). In order to exclude any genes that might
potentially be dysregulated due to off-target effects of one of the
siRNAs or the inhibitor, we selected genes that were consistently
differentially expressed following silencing of MELK with both
siRNAs and following treatment with OTS167 at a minimum of one
time point (Fig EV4B). We found that genes that were repressed by
abrogation of MELK activity (i.e. positively regulated by MELK)
were predominantly upregulated in prostate cancer compared to
benign tissue and in metastatic compared to primary prostate
cancers, confirming our hypothesis that MELK plays a role in cancer
progression (Fig 5A). Furthermore, MELK has previously been
shown to be positively regulated by Hes6 (Fig EV4D) and is part of
a HES6-associated signature that predicts poor outcome in prostate
cancer (Ramos-Montoya et al, 2014). About 43% of the genes in this
signature were also part of our putative MELK-upregulated gene set
(Fig 5B). Pathway analysis revealed that silencing of MELK or treat-
ment with OTS167 primarily resulted in changes in the expression
of genes associated with cell cycle regulation (Fig 5C), which was
consistent with previous studies suggesting that MELK plays a role
in the regulation of mitosis (Davezac et al, 2002; Badouel et al,
2006). Additional, potentially cancer-relevant pathways that were
affected by both MELK knock-down and OTS167 treatment included
apoptosis, cytoskeletal rearrangement and DNA damage repair
pathways.
Both silencing of MELK using siRNAs and treatment with
OTS167 strongly reduced viable cell numbers of C4-2b cells (Fig 5D
and E) and its castration-sensitive parental cell line LNCaP
(Fig EV4E and F). In a panel of five prostate cancer cell lines
(LNCaP, C4-2, C4-2b, PC-3 and DU145) and one non-transformed
prostate cell line (PNT1a), OTS167 suppressed cell viability with
IC50 values between 7.9 and 53.7 nM (Fig EV4G). This was similar
to results reported in other MELK-positive cancer cell line models
(Chung et al, 2012; Kato et al, 2016). Notably, there was a statisti-
cally significant correlation between MELK expression and sensitiv-
ity to OTS167, supporting the notion that the effects of OTS167 on
prostate cancer cell viability are at least partially mediated through
MELK (Fig 5F). OTS167 also dramatically reduced the clonogenic
ability of C4-2b cells (Fig 5G).
Taken together, these results strongly suggest that MELK
promotes the survival of prostate cancer cells and the expression of
genes associated with tumour progression.
Treatment with OTS167 suppresses prostate cancer growth
in vivo
Having demonstrated that silencing of MELK and treatment with
OTS167 greatly reduced prostate cancer cell proliferation and viabil-
ity in vitro, we aimed to evaluate whether targeting this kinase
might be a promising strategy to reduce tumour growth in vivo.
Treatment of mice bearing subcutaneous C4-2b xenografts with
OTS167 resulted in a strong reduction in tumour growth as demon-
strated by bioluminescence imaging (Fig 6A), measurement of
tumour volume (Fig 6B) and final tumour weights (Fig 6C). Staining
for cleaved caspase-3 (CC3) revealed that treatment with OTS167
induced apoptosis in these tumours (Fig 6D). To further validate the
◀ Figure 3. Identification of potential therapeutic targets in prostate cancer using cross-species analysis.A Expression patterns of the Cuzick signature mouse homologous genes in prostate tumours arising in the PB-Cre/PtenloxP/loxP and PB-Cre/p53loxP/loxPRbloxP/loxP models.
B Gene set enrichment analyses (GSEAs) comparing genes upregulated or downregulated in both mouse models to the Grasso human prostate cancer dataset. NES:
normalised enrichment score; PCa: prostate cancer.
C Strategy to identify potential therapeutic targets in prostate cancer. Genes that are upregulated in cancers of both mouse models (“Pten model (all lobes) and p53/Rb
model” in Fig EV1A) are identified, and this consensus signature is then compared to the Grasso human prostate cancer expression dataset using GSEA. Genes
forming the core enrichment in this analysis are filtered for druggability using The Drug Gene Interaction Database (DGIdb). The association of the expression of the
resulting candidate genes with poor outcome is then used to refine the list.
D Potential therapeutic targets identified using the strategy outlined in (C). The expression levels of the candidate genes in prostate tumours of the PB-Cre/PtenloxP/loxP
and PB-Cre/p53loxP/loxPRbloxP/loxP models are depicted as heatmaps.
Source data are available online for this figure.
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Figure 4. MELK is overexpressed in human prostate cancer and associated with an aggressive phenotype.
A Kaplan–Meier plot showing that the high expression of MELK is associated with shorter time to relapse in the Cambridge dataset (Ross-Adams et al, 2015). Cut-offs
for MELK expression levels were determined by recursive partitioning. Statistical significance was assessed by Log-rank test.
B Expression of MELK in the five prostate cancer iClusters identified in the Cambridge dataset (Ross-Adams et al, 2015). Horizontal line indicates median; box limits
correspond to 75th and 25th percentiles; whiskers correspond to 95th and 5th percentile.
C Representative tissue microarray images of immunohistochemical staining for MELK in benign prostate (n = 148), PIN (n = 38), low-grade and high-grade prostate
cancer (n = 323). Scale bars correspond to 200 lm.
D Quantification of immunohistochemical staining for MELK on the tissue microarray. Chi-square test was performed comparing samples with any positive staining for
MELK (regardless of localisation) to samples negative for MELK; black outlines indicate groups.
E Cytoplasmic MELK expression is associated with increased Gleason score and higher tumour stage. Samples with cytoplasmic MELK were tested against samples with
nuclear MELK only using chi-square test for Gleason score and Fisher’s exact test for tumour stage. CGS: combined Gleason score.
Source data are available online for this figure.
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anti-apoptotic role of MELK in prostate cancer, we treated C4-2b
cells with OTS167 in vitro and assessed the rate of apoptosis using
Annexin V staining. Consistent with our findings in vivo, we
observed an increase in the fraction of apoptotic cells (Fig 6E). The
same effect was observed following silencing of MELK using
siRNAs, supporting the interpretation that this effect of the drug
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Figure 5. Abrogation of MELK activity downregulates tumour-relevant genes and suppresses cancer-associated phenotypes.
A GSEA comparing genes repressed by both silencing and inhibition of MELK to the Grasso human prostate cancer dataset. C4-2b cells were transfected with siRNAs
directed against MELK for 72 h, or treated with 30 nM OTS167 for 8 and 24 h, and subjected to RNA sequencing (n = 4). Genes that were significantly downregulated
(Padj < 0.05) by both siRNAs and by OTS167 at at least one time point were considered as positively regulated by MELK. NES: normalised enrichment score; PCa:
prostate cancer; Met: metastases.
B Overlap between MELK-regulated genes and Hes6 signature (Ramos-Montoya et al, 2014).
C Altered process networks following MELK abrogation. Differentially expressed genes for each treatment condition were identified (Padj < 0.05), and the 50 most
enriched process networks in each condition were computed using Metacore enrichment analysis. Enriched process networks were ranked according to their P-value,
and the ranks of the 10 most enriched process networks across all four conditions were visualised as a heatmap.
D Effect of silencing of MELK on proliferation of prostate cancer cells. C4-2b cells were transfected with siRNAs directed against MELK or a non-targeting control, and
viable cells were counted after 4 and 7 days. n = 4.
E Effect of OTS167 on proliferation of prostate cancer cells. C4-2b cells were treated with vehicle or OTS167 at varying concentrations, and viable cells were counted
after 2 and 5 days. n = 3.
F Correlation between MELK expression and sensitivity to OTS167. MELK mRNA levels in prostate cell lines were determined by qRT–PCR, n = 4 for all cell lines, except
C4-2b (n = 5). The IC50 for OTS167 in each cell line was determined (see Fig EV4F). The correlation between MELK expression and OTS167 IC50 was assessed by
Pearson correlation coefficient.
G Effect of OTS167 on clonogenic ability of prostate cancer cells. C4-2b cells were seeded at low confluence and grown in presence of vehicle or varying concentrations
of OTS167 for 9 days. Colonies were stained with crystal violet, and total colony volume was quantified. n = 3.
Data information: Statistical significance was assessed by randomised blocks ANOVA (significance threshold of 0.05) followed by Holm–Sidak’s multiple comparisons test
in panels (D, E and G).
Source data are available online for this figure.
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could be mediated through MELK (Fig 6F). In conclusion, treatment
with OTS167 induced apoptosis in prostate cancers in vivo and abro-
gated tumour growth.
Treatment with OTS167 reduces phosphorylation of stathmin
and interferes with mitotic spindle formation
To better understand both MELK-dependent and MELK-independent
effects of OTS167 that might contribute to its anti-tumour effects
in vitro and in vivo, we performed an antibody array interrogating
674 phosphorylation sites on 400 proteins, using lysates from
OTS167-treated C4-2b cells.
We identified 147 phosphorylation sites that passed our quality
control and exhibited log2-fold changes of > 0.5 (Table EV2;
Fig 7A). Many cancer-relevant signalling pathways were affected by
OTS167; one example was the p90RSK pathway, with several acti-
vating sites of p90RSK and phosphorylation sites on three of its
substrates, including an inhibitory phosphorylation site on the
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Figure 6. OTS167 suppresses prostate cancer growth in vivo.
A OTS167 reduces growth of prostate cancer xenografts. Luciferase-expressing C4-2b xenograft tumours were established in NOD scid gamma mice for 7 days. Animals
were subsequently dosed with 10 mg/kg OTS167 i.p. daily. Bioluminescence was measured once per week. n = 10. Statistical significance was assessed using the
Holm–Sidak method (a = 5%). Arrow indicates start of dosing with vehicle or OTS167.
B The growth of xenografts in (A) was followed by calliper measurements twice per week from day 10, when tumours first became palpable. n = 10. Statistical
significance was assessed using the Holm–Sidak method (a = 5%).
C Xenograft tumours in (A) were weighed after sacrifice. n = 10 for vehicle group, n = 8 for OTS167 group. Statistical significance was assessed by Mann–Whitney test.
Horizontal line indicates median; box limits correspond to 75th and 25th percentiles; whiskers indicate minimum and maximum.
D Effect of OTS167 on apoptosis of xenograft tumours. Xenograft tumours were stained for cleaved caspase-3 (CC3) as a read-out for apoptosis induction, and CC3-positive
cells were quantified. n = 10 for vehicle group; n = 8 for OTS167 group. Statistical significance was assessed by Mann–Whitney test. Scale bars correspond to 200 lm.
Horizontal line indicates median; box limits correspond to 75th and 25th percentiles; whiskers indicate minimum and maximum.
E Effect of OTS167 on apoptosis of prostate cancer cells. C4-2b cells were treated with vehicle or OTS167 at varying concentrations for 48 h, and apoptotic, live and
dead cells were quantified by Annexin V/propidium iodine staining followed by flow cytometry analysis. Statistical significance of the differences between the
proportions of apoptotic cells was tested by randomised blocks ANOVA (significance threshold of 0.05) followed by Holm–Sidak’s multiple comparisons test. n = 3.
F Effect of MELK siRNA on apoptosis of prostate cancer cells. C4-2b cells were transfected with siRNAs directed against MELK for 4 days, and apoptotic, live and dead
cells were quantified by Annexin V/propidium iodine staining followed by flow cytometry analysis. Statistical significance of the differences between the proportions
of apoptotic cells was tested by randomised blocks ANOVA (significance threshold of 0.05) followed by Holm–Sidak’s multiple comparisons test. n = 4.
Source data are available online for this figure.
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pro-apoptotic protein BAD, showing clear reductions (Fig EV5A).
This was also confirmed by Western blot (Fig 7B).
The two most significantly reduced phosphorylation events
on the antibody array were Ser16 and Ser38 of the microtubule-
destabilising protein stathmin (Fig 7A). Stathmin is inhibited by
phosphorylation upon entry into mitosis, enabling the mitotic
spindle to form, and subsequently dephosphorylated to allow
depolymerisation of the spindle and exit from mitosis (Rubin &
Atweh, 2004). Studies using stathmin mutants that could not be
phosphorylated have shown that failure to deactivate stathmin upon
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Figure 7. Inhibition of MELK reduces phosphorylation of stathmin and interferes with mitotic spindle formation.
A Identification of phosphorylation sites affected by OTS167. C4-2b cells were treated with vehicle or 30 nM OTS167 for 2 h, and phosphoproteins were analysed using
a Phospho Explorer Antibody Array. Signals for each phosphorylation site were normalised to its corresponding total protein. Top upregulated and downregulated
phosphorylation sites are shown. n = 1.
B Validation of effects of OTS167 on phosphorylation of p90RSK and its targets. C4-2b cells were treated with vehicle or 30 nM OTS167 for the indicated times, and
levels of total and phosphorylated proteins were determined by Western blot analysis. b-Actin was used as a loading control.
C Treatment with OTS167 reduces phosphorylation of stathmin at Ser-38. C4-2b cells were treated with vehicle or 30 nM OTS167 for the indicated times, and levels of
total and phosphorylated stathmin were determined by Western blot analysis. b-Actin was used as a loading control.
D Treatment with OTS167 results in formation of abnormal mitotic spindles. C4-2b cells were treated with vehicle or 30 nM OTS167 for 24 h. Mitotic spindles and DNA were
visualised by immunofluorescent staining for a-tubulin, and by staining with DAPI, respectively. Scale bars correspond to 10 lm. For vehicle-treated cells, examples of
normal metaphase (I), anaphase (II) and telophase (III) are shown. For OTS167-treated cells, normal mitotic phases could not be observed. Note mis-attached chromosomes
(arrows). Intact and defective spindles were quantified by counting 100mitotic cells per experimental condition. Significance was assessed using the chi-square test.
Source data are available online for this figure.
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mitotic entry results in cell cycle arrest and the formation of abnor-
mal spindles (Segerman et al, 2003). We thus hypothesised that
OTS167 might interfere with mitotic spindle formation.
To address this hypothesis, we validated the decrease in stath-
min phosphorylation induced by OTS167 by Western blot (Fig 7C).
We then tested whether OTS167 would induce a similar phenotype
of abnormal mitotic spindles as had been described for constitu-
tively active stathmin mutants. Indeed, we observed that the major-
ity of OTS167-treated cells failed to form an ordered metaphase
plane and instead exhibited abnormal mitotic spindles showing
features characteristic of excess microtubule catastrophe promotion
(Segerman et al, 2003; Holmfeldt et al, 2004), namely disorganised
chromosomes, decreased amount of kinetochore microtubules and
starlike asters with short, dense microtubules (Fig 7D).
Notably, the reduction in phospho-stathmin following OTS167
treatment was also observed in xenograft tissue, confirming that this
effect also occurs in an in vivo setting. Due to the small size and
extensive cell death of OTS167-treated xenograft tumours, we were
only able to extract sufficient amounts of protein from four tumours
of this treatment arm. Three out of these four samples showed
reduced levels of stathmin phosphorylation compared to samples
from vehicle-treated animals (Fig EV5B). Notably, the one sample
that did not exhibit decreased phospho-stathmin levels was obtained
from an animal whose tumour responded relatively poorly to
OTS167 (Fig EV5C).
Interestingly, the known cell cycle-dependent pattern of stathmin
phosphorylation correlates well with the previously reported
increase in MELK activity during mitosis (Blot et al, 2002). Inhibi-
tion of stathmin phosphorylation might thus be a MELK-dependent
effect of OTS167. Consistent with this notion, silencing of MELK
resulted in a similar decrease in stathmin phosphorylation as
observed following OTS167 treatment (Fig EV5D).
In conclusion, our data suggest that one of the mechanisms
through which OTS167 induces cell death may involve decreased
phosphorylation of stathmin, resulting in defective mitotic spindles,
and that this may be mediated by MELK.
Discussion
GEMM of cancer represent powerful tools for understanding tumour
biology. The data described in this study represent the most in-
depth molecular characterisation of the PB-Cre/PtenloxP/loxP model
and PB-Cre/p53loxP/loxPRbloxP/loxP models of prostate cancer to date.
They provide insight into the different stages of tumour progression
in these models as well as the similarities and differences of
tumours arising in each of the four prostatic lobes.
The main aim of this study was to use the acquired data from
GEMM to prioritise potential therapeutic targets for functional vali-
dation. Several lines of evidence suggest that this cross-species
approach resulted in the identification of genes that have the poten-
tial to be therapeutic targets in PCa. Firstly, among the 10 identified
candidates, there are a number of genes that are known to play
important roles in cancer biology, such as key cell cycle regulators
(e.g. Bub1, Bub1b, Cdc25c, Cdk1), and BIRC5 and Top2a. Secondly,
a statistically significant association between high expression of the
genes and decreased relapse-free survival was found for 6 out of 10
genes. Finally, the protein kinase MELK was chosen for functional
validation to provide proof of principle that potential therapeutic
targets were identified.
A number of publications support the notion that MELK is a key
regulator of progression and potential therapeutic target in multiple
cancer types (Gray et al, 2005; Alachkar et al, 2014; Wang et al,
2014).
We found that MELK is overexpressed in human prostate
tumours on the protein level, consistent with a previous study
(Kuner et al, 2013). Interestingly, we observed that only cytoplas-
mic, but not nuclear, MELK was associated with parameters of
aggressiveness. The underlying mechanisms as well as the func-
tional consequences of this change in MELK localisation will require
further investigation. However, one previous study in glioblastoma
has already hinted at the possibility of differential functions for
nuclear and cytoplasmic MELK (Gu et al, 2013).
Our data suggest that inhibition of MELK has the potential to be
an effective therapeutic strategy in prostate cancer. We found that
treatment with OTS167 reduced the viability of prostate cancer cells
at nanomolar concentrations, abrogated growth of xenograft
tumours and induced apoptosis of tumour cells both in vitro and
in vivo. The MELK inhibitor used in this study, OTS167, is currently
being tested in oncology clinical trials and has been shown to be
effective in xenograft models of several cancer types (Chung et al,
2012; Wang et al, 2014). It has recently been suggested that the
anti-proliferative effects of OTS167 on breast cancer cells are medi-
ated through off-target effects, as MELK-knockout cell lines
remained sensitive to the inhibitor (Huang et al, 2017; Lin et al,
2017); however, no such findings have been reported in other
cancer types to date. While we cannot fully exclude that off-target
effects of OTS167 may have contributed to some of the phenotypes
observed in our study, we obtained highly consistent results with
both OTS167 and two separate siRNAs directed against MELK, most
notably with regard to inhibition of proliferation, induction of apop-
tosis and reduced phosphorylation of stathmin. We also limited our
analysis of the effects of MELK on gene expression to genes that
were consistently affected by both OTS167 and two independent
siRNAs directed against MELK, which is expected to result in a
strong enrichment for bona fide MELK-regulated genes.
Other than MELK, only a small number of kinases that are also
inhibited by OTS167 have been described so far; interestingly, one
of them is the mitotic checkpoint kinase BUB1 (Ji et al, 2016). BUB1
was among the 10 potential therapeutic targets that were identified
by our cross-species approach (Fig 3D), and its association with
poor outcome across multiple independent cohorts was almost as
compelling as the one observed for MELK (Fig EV2B). Based on our
cross-species data, we would thus predict a compound such as
OTS167, which is able to inhibit both MELK and BUB1, to be more
effective in targeting prostate cancer cells than single inhibitors of
either kinase. A similar approach has already been proposed in
kidney cancer cells, where combined targeting of MELK and another
kinase, TOPK, was shown to have stronger growth-suppressive
effects than targeting either kinase on its own (Kato et al, 2016).
We also identified several downstream targets affected by
OTS167 in prostate cancer cells, including the pro-apoptotic protein
BAD and the microtubule-associated protein stathmin. Interestingly,
a previous study found that breast cancer cells treated with OTS167
failed to complete mitosis and subsequently underwent apoptosis
(Wang et al, 2014). It is possible that loss of stathmin
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phosphorylation and the resulting disruption of the mitotic spindle
are the underlying mechanism behind this phenotype.
Further studies will be required in order to dissect which of the
downstream effects of OTS167 identified in this study are mediated
through MELK and which involve other kinase targets. The develop-
ment of novel, potentially more specific inhibitors of MELK would
be an important step in facilitating this research. Efforts in this
direction are already underway, and several other molecules have
been reported to inhibit MELK; however, so far these are signifi-
cantly less potent than OTS167 (Huang et al, 2017).
Considering that silencing of MELK also decreased stathmin
phosphorylation, it would be interesting to confirm whether this is
one of the downstream effects of OTS167 that are mediated through
MELK. While MELK had previously been shown to play a role in
mitosis (Davezac et al, 2002; Wang et al, 2014), it has not yet been
reported to regulate mitotic spindle formation. If confirmed, this
would thus constitute a novel function of this kinase. As a next step,
it would be worthwhile to test whether stathmin is a direct substrate
of MELK. As the consensus phosphorylation motif for MELK is so
far unknown, we were unable to determine whether stathmin has a
potential MELK phosphorylation site.
Recently, Mu et al (2017) and Ku et al (2017) showed that pros-
tate tumour progression to anti-androgen resistance involves a
mechanism named cellular lineage plasticity, in which the repro-
gramming transcription factors SOX2 and EZH2 play a role in induc-
ing stemness, neuroendocrine phenotype and canonical androgen
receptor signalling independence. Interestingly, MELK activity
together with FOXM1 has been shown to positively regulate both
SOX2 and EZH2 in other tumours, such as glioma and medulloblas-
toma (Ganguly et al, 2014; Kim et al, 2015; Liu et al, 2017). Similar
complex signalling may occur in advanced stages of PCa, opening
new strategies for castration-resistant prostate cancer therapies in
the context of resistance to new anti-androgens (enzalutamide) and
androgen synthesis inhibitors (abiraterone) (Narayanan et al, 2015).
In conclusion, our data demonstrate that cross-species integra-
tion of genomic data from cancer GEMM and human cancer patients
is a powerful strategy to identify potential therapeutic targets. The
protein kinase MELK constitutes an example of a potential therapeu-
tic target that has been predicted using this method and validated
using a combination of genomic analyses, survival data and in vitro
and in vivo studies.
Materials and Methods
Mice
FVB.129-Trp53tm1Brn(01XC2) and FVB.129-Rb1tm2Brn (01XC1) mice
were kindly obtained from the NCI Mouse Models of Human
Cancers Consortium (MMHCC) on behalf of Anton Berns (Nether-
lands Cancer Institute). B6.D2-Tg(Pbsn-cre)4Prb (01XF5) mice were
kindly obtained from MMHCC on behalf of Pradip Roy-Burman
(University of Southern California). C.129S4-Ptentm1Hwu/J mice were
obtained from The Jackson Laboratory (Bar Harbor, ME). All strains
were backcrossed N11 to an FVB/N genetic background. For tumour
implantation, immunocompromised (NOD/scid/IL2R gamma null or
NSG) male mice (Charles River, Wilmington, MA) were used. Mice
were maintained in the Cancer Research UK Cambridge Institute
Animal Facility. All experiments were performed in accordance with
national guidelines and regulations and with the approval of the
animal care and use committee at the institution under UK Home
Office project licence 80/2435.
In vivo studies and mouse prostate samples for RNA sequencing
For xenograft studies, two million luciferase-expressing C4-2b cells
were injected subcutaneously in the flank of male NSG mice in a 1:1
mix of PBS and phenol red-free HC matrigel (BD, Franklin Lakes,
NJ). Tumours were established for 1 week. Following that, mice
were dosed daily with 10 mg/kg OTS167 in PBS + 10% DMSO
intraperitoneally. Grafts were monitored biweekly by calliper
measurement and weekly by imaging after intraperitoneal injection
of D-luciferin 150 mg/kg (Caliper Life Sciences, Hopkinton, MA).
Luminescent measurements were analysed using Xenogen Imaging
Analysis software “Living Image 3.0” (Caliper Life Sciences) and
plotted as photons/second for graphic analysis of growth kinetics.
Mice were culled at completion of experiment or when tumours
reached 10% of body weight. To select prostate tumour samples,
prostate lesions were histopathologically classified according to
recommendations from the Mouse Models of Human Cancer
Consortium Prostate Pathology Committee (Shappell et al, 2004;
Ittmann et al, 2013). Human genome version hg19 or the mouse
genome version mm10 was used to align sequencing reads.
Gene set enrichment and survival analyses
Gene set enrichment analysis (GSEA) was performed using the
GSEAPreranked tool within the GSEA software (Broad Institute,
The paper explained
Problem
Genome-wide expression datasets from human prostate tumours
readily allow the identification of genes whose expression levels are
altered during cancer development and progression. However, trans-
lating this information into clinically useful therapeutic targets poses
a twofold challenge: firstly, many genes may be aberrantly expressed
as a consequence of cancer development without directly contributing
to it, and secondly, not all functionally important genes will represent
actionable targets for current drug development approaches.
Results
We used genetically modified mouse models of prostate cancer to
identify genes that are aberrantly expressed in both human and
murine prostate cancers. Through a series of filtering steps, we identi-
fied a list of potential therapeutic targets for prostate cancer treat-
ment. We validated one of these potential therapeutic targets, the
protein kinase MELK, by showing that silencing of this gene inhibits
prostate cancer cell proliferation and induces cell death in vitro. Treat-
ment with a compound that inhibits MELK strongly reduced prostate
cancer growth in vivo.
Impact
Our results show that cross-species comparisons of mouse and
human prostate cancer gene expression data can identify potential
therapeutic targets. Inhibition of one of these potential targets, the
kinase MELK, might be a promising strategy for treatment of prostate
cancer.
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http://www.broadinstitute.org/gsea/index.jsp; Mootha et al, 2003;
Subramanian et al, 2005), and process networks enriched among
gene sets of interest were identified with the one-click process
networks enrichment analysis tool within MetaCoreTM (Thomson
Reuters, Cambridge, UK). Survival analysis was carried out using a
Galaxy-based (https://galaxyproject.org/) tool developed by the
Cancer Research UK Cambridge Institute Bioinformatics Core
Facility.
Cell lines and cell-based assays
LNCaP, PC-3 and DU-145 cells were obtained from ATCC (Manas-
sas, VA, USA), C4-2 and C4-2b from MD Anderson Cancer Center
(Houston, TX, USA). OTS167 was sourced from Haoyuan Chemex-
press (Shanghai, China) and dissolved in DMSO. siRNAs against
MELK (MELK siRNA #1: Qiagen SI02224558; MELK siRNA #2:
Qiagen SI02224565; MELK siRNA #3: Dharmacon J-004029-06) were
transfected (final 20 nM) using Lipofectamine RNAiMAX (Invitro-
gen). AllStars Negative Control siRNA (Qiagen SI03650318) was
used as a non-targeting control. Cell viability and proliferation were
assessed using Vi-CELL and MTS assays. Apoptotic cells were quan-
tified based on Annexin V and PI staining using a FACS Calibur (BD
Biosciences). Clonogenicity assays were quantified using a GelCount
imaging system.
Antibody arrays, western blot, qRT–PCR, immunohistochemistry
and immunofluorescence
Antibody arrays were analysed using Phospho Explorer Antibody
Arrays (Full Moon Biosystems, Sunnyvale, CA, USA). Western blots
were performed for anti-RRN3 pSer649 (ab138651) and anti-b-actin
(ab6276), both from Abcam, Cambridge, UK; anti-stathmin pSer38
(4191), anti-p90RSK pThr573 (9346), anti-Bad pSer112 (9291), anti-
RSK1/2/3 (9355), anti-Bad (9292) and anti-stathmin (3352), all from
Cell Signalling Technology, Cambridge, UK; anti-a-tubulin (T9026)
and anti-MELK (HPA017214), all from Sigma-Aldrich, St Louis, MO,
USA; anti-RRN3 (sc-133978), from Santa Cruz Biotechnology,
Dallas, TX, USA; and anti-MELK (NBP1-19598), from Novus Biologi-
cals, Littleton, CO, USA. IF was performed for a-tubulin (DM1A,
Sigma) and IHC for MELK (NBP1-19598, Novus Biologicals, Little-
ton, CO, USA) and CC3 (9664, Cell Signalling Technology). qRT–
PCRs were performed on an ABI PRISM 7900 HT Sequence Detec-
tion System. Relative gene expression was calculated according to
the ΔΔCt method; HPRT was used as housekeeping gene.
Data analysis and graphical representation
Statistical analysis was performed in GraphPad Prism6 unless other-
wise indicated. Parametric tests were used in cases where normal
distribution could be assumed based on prior similar studies; other-
wise, non-parametric tests were used. Details of statistical tests used
and number of replicates are given in the respective figure legends.
All error bars indicate standard error of mean unless otherwise
stated, and n indicates independent biological replicates. No power
analysis was done a priori of study design, since the effect size in
changes was unknown.
Hypergeometric tests were performed in R version 3.1.1 (R Core
Team, 2014) using the phyper function in the stats package.
Heatmaps were generated using the gplots and RColorBrewer pack-
ages. In case of RNAseq data, normalised counts were used as the
input.
Data availability
Study data are deposited in NCBI Gene Expression Omnibus
(https://www.ncbi.nlm.nih.gov/geo/) under accession numbers
GSE94570 (MELK-regulated genes) and GSE94574 (mouse prostate
lobe gene expression).
Additional methods
Expanded methodology and details of reagents used for in vivo
studies, selection and preparation of mouse prostate samples for
RNA sequencing, gene set enrichment analysis, survival analysis,
tissue microarray, cell lines and culture conditions, transfection,
viability, apoptosis, clonogenicity, antibody array, Western blot,
immunofluorescence, immunohistochemistry, qRT–PCR, data
analysis and graphical representation, antibodies, primers, probes
and oligonucleotides are described in Appendix Supplementary
Methods.
Expanded View for this article is available online.
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